Dianthus Therapeutics, Inc. /DE/

DNTH - CIK 0001690585

Market cap$4.18 B

Rank#1530

SEC filings624

Dianthus Therapeutics, Inc. /DE/ trades as DNTH and has a market capitalization of $4.18 B, making it the #1530 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.04M, down 67.3% from the prior year and net income of -$162.34M. This page tracks Dianthus Therapeutics, Inc. /DE/ through 624 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$2.04MFY 2025

Net income (latest FY)-$162.34MFY 2025

Operating cash flow (latest FY)-$129.06MFY 2025

Total assets (latest FY)$530.92MFY 2025

Net margin-7973.3%latest FY

Financial performance

Net profit margin compressed from -888.1% to -7973.3% over the same period - every figure below comes from the company's audited annual filings.

DNTH annual revenueView details

Key statistics

Market cap: $4.18 B
Share price (derived)market cap / shares outstanding: $76.42
EPS (diluted)FY 2025: $-4.20
Shares outstandingas of 2026-05-01: 0.05B
Total equityas of 2026-03-31: $1.20B
Return on equity: -13.5%
Cash & equivalentsas of 2026-03-31: $627.67M
Current ratioas of 2026-03-31: 29.25

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Major company event	8-K	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22

Browse the full filing history (624 filings)

Recent press releases

Investor Conference Call & Webcast Information2026-05-22
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Dianthus Therapeutics
Dianthus Therapeutics Participate Two Investor Conferences2026-05-22
Dianthus Therapeutics to Participate in Two Investor Conferences | Dianthus Therapeutics
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results2026-05-22
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results | Dianthus Therapeutics
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-05-22
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Dianthus Therapeutics
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-05-22
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Dianthus Therapeutics

Similar companies

The largest companies sharing Dianthus Therapeutics, Inc. /DE/'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.070 T DNTH vs LLY

JNJJohnson & Johnson$574.10 B DNTH vs JNJ

ABBVAbbVie Inc.$397.44 B DNTH vs ABBV

MRKMerck & Co., Inc.$294.13 B DNTH vs MRK

AZNAstraZeneca PLC$286.27 B DNTH vs AZN

Frequently asked questions

What is Dianthus Therapeutics, Inc. /DE/'s market cap?

Dianthus Therapeutics, Inc. /DE/ (DNTH) has a market capitalization of $4.18 B as of 2026-06-11, ranking #1530 among US-listed companies.

How much revenue does Dianthus Therapeutics, Inc. /DE/ make?

Dianthus Therapeutics, Inc. /DE/ reported revenue of $2.04M for fiscal year 2025, a decrease of 67.3% year over year.

Is Dianthus Therapeutics, Inc. /DE/ profitable?

In its latest fiscal year Dianthus Therapeutics, Inc. /DE/ reported a net loss of $162.34M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.